These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Naloxone potentiation of novelty-induced hypoalgesia: characterization of the alpha-noradrenergic receptor subtype.
    Author: Rochford J, Dawes P, Stewart J.
    Journal: Pharmacol Biochem Behav; 1993 Feb; 44(2):381-6. PubMed ID: 8383341.
    Abstract:
    Repeated daily administration of the opiate receptor antagonist naloxone (10 mg/kg) attenuates the habituation of novelty-induced hypoalgesia. This effect can be reversed by the alpha 2-noradrenergic receptor agonist clonidine and enhanced by the alpha 2-antagonist yohimbine. The present experiments were conducted to provide further support for the importance of the alpha 2-receptor and determine the possible influence of the alpha 1-receptor. Naloxone's effect on novelty-induced hypoalgesia was not affected by pretreatment with the specific alpha 1-receptor antagonist prazosin (0.2-1.0 mg/kg, SC) or the nonselective alpha antagonist phentolamine (2.0-10.0 mg/kg). In a second series of experiments, it was found that the potentiation of naloxone's effect by yohimbine (2 mg/kg) was reversed by clonidine (0.1 mg/kg) but was not influenced by prazosin or phentolamine. These results suggest that the alpha 1-noradrenergic receptor subtype does not mediate the effect of naloxone on novelty-induced hypoalgesia. They also reinforce the importance of the alpha 2-receptor subtype in the mediation of this effect.
    [Abstract] [Full Text] [Related] [New Search]